Qiagen (NYSE:QGEN) Hits New 52-Week High – What’s Next?

Qiagen (NYSE:QGEN)’s share price reached a new 52-week high during trading on Tuesday . The company traded as high as $47.50 and last traded at $47.40, with a volume of 135459 shares traded. The stock had previously closed at $46.00.

Analyst Ratings Changes

QGEN has been the subject of several research analyst reports. Hsbc Global Res raised Qiagen to a “hold” rating in a research note on Thursday, October 17th. Jefferies Financial Group reiterated a “buy” rating and set a $54.00 price objective (up from $42.00) on shares of Qiagen in a research report on Tuesday, December 10th. Morgan Stanley reissued an “equal weight” rating and issued a $48.00 price objective (down previously from $50.00) on shares of Qiagen in a research note on Monday, January 6th. Finally, HSBC cut shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a research note on Thursday, October 17th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $51.50.

Qiagen Trading Down 0.5 %

The business has a 50 day moving average of $44.43 and a two-hundred day moving average of $44.22. The firm has a market capitalization of $10.79 billion, a price-to-earnings ratio of 121.18, a P/E/G ratio of 3.51 and a beta of 0.37. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17.

Institutional Trading of Qiagen

Hedge funds and other institutional investors have recently bought and sold shares of the business. Wellington Management Group LLP boosted its position in shares of Qiagen by 77.7% during the third quarter. Wellington Management Group LLP now owns 21,250,943 shares of the company’s stock valued at $963,386,000 after buying an additional 9,293,040 shares during the last quarter. Earnest Partners LLC lifted its stake in Qiagen by 11.1% during the 2nd quarter. Earnest Partners LLC now owns 3,807,284 shares of the company’s stock valued at $156,441,000 after acquiring an additional 379,679 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in Qiagen by 62.6% during the 3rd quarter. Victory Capital Management Inc. now owns 2,574,705 shares of the company’s stock worth $117,329,000 after acquiring an additional 991,325 shares during the last quarter. State Street Corp boosted its holdings in Qiagen by 3.9% during the 3rd quarter. State Street Corp now owns 2,380,008 shares of the company’s stock worth $108,457,000 after acquiring an additional 90,181 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Qiagen by 16.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,320,088 shares of the company’s stock worth $105,726,000 after acquiring an additional 324,417 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.